Certara, Inc.


SKU: CERT Category:


Certara, Inc.: Initiation Of Coverage –  A Diverse Product Portfolio & Interesting AI Initiatives!


This is our first report on Certara, a renowned biosimulation player. The company recently released its Fourth Quarter 2023 Earnings. In terms of performance, the company reported revenue growth of 6% for the year, in line with their guidance from August 2023. Growth was particularly high in software sales, which rose by 14% over the full year, while technology-enabled services saw a modest increase of 1%. Record-breaking sales were reported in the fourth quarter and an uptick in technology-enabled service bookings in the latter half of the year highlighted the growing acceptance of the Certara’s product offerings among its industry peers.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!